For oral use

Full Spectrum Phytocannabinoids Formulations

GrowLab Pharmaceuticals’ phytocannabinoids formulations contain the two main active pharmaceutical ingredients: Cannabidiol (CBD) and Tetrahydrocannabinol (THC), as well as all other medicinal compounds of the cannabis plant such as Terpenes.

For the best possible therapy for your patients



Comacadine® is a GrowLab Pharmaceuticals’ proprietary DNA-specific genetic diploid Indica breed with high yield of Phytocannabinoids such as Cannabidiol (“CBD”) and Terpenoids, but with zero or minimal Tetrahydrocannabinol (“THC”). The botanical name is COCOMACADINE. It derives its native name from KOKOMAKADI village in West Africa.


Comacadine® is a full spectrum Phytocannabinoid-derived and Terpenoid-derived therapeutic synthesised into a biopharmaceutical medicinal formulation in compliance with European Medicines

Agency cGMP requirements.
The deflowered leaf of COCOMACADINE can be smoked when cured, but does not generate psychoactive effect because of zero THC.

The Medicinal Benefits of Comacadine® :
Comacadine ® is very efficacious in treatment of Diabetes Mellitus and the reduction of high blood pressure.

Mechanism of Action

It is systemic and acts via peripheral circulation, carbenoid from Comacadine® increases the peripheral vessels dilation especially microvasculature arterioles – capillaries – vessels. This increases the peripheral blood flow and circulations of nutrients to the part of the body that is far away from the heart – ankles-feet and chin. This is also the part of the body that is mainly prone to diabetics wound (ulcers). This distal part of the body is poor in blood supply – because it is mainly covered by tenders and skin. This vasodilatory effect of Phytocannabinoids of Comacadine® increases
blood flow, which reduces pressure from heart pumping.

Mechanism of Action of Phytocannabinoids from Comacadine®

Its Phytocannabinoids exert its effect via interaction with the CB1R (endocannabinoid type 1 receptor) and CB2R (endocannabinoid type 2 receptor). CB1Rs are abundant in the brain, and are in regions associated with pain, memory, calmness among others, and CB2R are mostly found in the periphery on immune cell lymphoid tissue, and peripheral nerve terminals.
CB1R and CB2R interact with endogenous ligands including anandamides, which are arachidonic acid derivatives. The endogenous system modulates neuronal activity via cyclic amp, ca2 transport, and K+ ions and is thought to be associated with opioid, GABAergic, dopaminergic and several other systems via reduces chronic neuropathic pain of diabetic wound, chronic malignant ulcer pains and produces calmness and stabilization of brain.


Comacadine® is a GrowLab Pharmaceuticals’ proprietary DNA-specific genetic diploid Indica breed with high yield of Phytocannabinoids such as Cannabidiol (“CBD”) and Terpenoids, but with zero or minimal Tetrahydrocannabinol (“THC”). The CBD of Comacadine® has a specific characteristic when smoked; which is to refresh brain and generate calmness. This particular characteristic made us to go into the detailed study and research on the non-psychoactive Phytocannabinoids extracted from it.
The biopharmaceutical formulation of Comacadine® is rich in Phytocannabinoids such as CBD and Terpenes synthesised into a proprietary bio-formulation of this particular species of cannabis called (Cocomacadine).


From GrowLab Pharmaceuticals’ randomised clinical trials conducted under special research permit in collaboration with Biotech Research Laboratories; Pharmacy Department of the University of Nigeria NSUKKA, Comacadine® was clinically studied on its efficaciousness in reducing sugar level especially in people with disease associated with high sugar in the blood such as Diabetes Mellitus.

About Diabetes Mellitus:
Diabetes mellitus is an autoimmune genetical disease whereby glucose (sugar) is found to be accumulated in the blood. This is as a result of either Lack of Insulin (that is insulin dependent diabetic mellitus) or body not responding normally to insulin, causing blood sugar (glucose) level to be high. These elevated levels of blood glucose (or blood sugar) can lead overtime to serious health conditions and complications such as:

  • Diabetic Neuropathy – tingling sensation and diabetic leg ulcer.

  • Diabetic Retinopathy – blurred vision and blindness.

  • Diabetic Nephropathy – kidney disease and failure.

Comacadine® has been found to be efficacious in reducing the sugar levels in patients undergoing the clinical trials much better than insulin and other insulin related drugs such as Metformin and Glibenclamide. These processes and findings have been following up diligently by serially measuring the sugar level of those patients using (glucometer) on daily basis. The results have been very interesting and fantastic since the onset of the studies. Patients have expressed remarkable normalisation of the blood sugar levels. Comacadine® is easy to take as it is in liquid and capsule form unlike the insulin that is injectable. Patients are free from continuous daily needle prick and injection. The action of Comacadine® on blood sugar is gradually and continuously over long period of say 16-20 hours (long acting); it is these characteristics of long acting that the fear of hypoglycaemia and hypoglycaemic coma is not there which is the major complication of insulin and insulin related drugs to patients taking them.

The effect of Comacadine® on the eye
The vasodilatory effect of Comacadine® on microvasculature of retina blood vessels, and increase blood flow to the retina on the eyes makes it possible to clear the blurring vision associated with diabetic retinopathy. Those patients on the clinical trials are testifying to the great improvement on their eye sights following the use of Comacadine®. It is also found to be reducing intraocular pressure in those that are suffering from glaucoma. Comacadine® is good in treatment of glaucoma which is a disease condition associated with age and is a result of increase in intraocular pressure.
This increase in intraocular pressure make it impossible for the patient to see clearly, but with Comacadine® those patients taking it have been enjoying good sight and are celebrating the discovery.

The other health benefit of Comacadine® therapeutic formulation includes quick relief of pain associated with Rheumatoid arthritis and osteoarthritis of the joint. The pain of arthritis can be excruciating but those taking Comacadine® are happy with the way the therapeutic formulation has improved their quality of life. No doubt it has to do with the analgesic properties of the Phytocannabinoids and Terpenes with their effect on both peripheral and central nerve endings.
Comacadine® also has inhibitory effect of Rheumatoid Factor (RF) in the blood which helps to reduce pain. The Rheumatoid Factor (RF) that has been testing POSITIVE on some of the patients on Comacadine® therapeutic trials are found to test NEGATIVE during clinical trials. More studies and research are still going on in this specialized formulation, mechanism of action, as well as the dose and dosages of Comacadine®.


Thanks to controlled tests and high-quality production systems, we can always guarantee the consistently high pharmaceutical quality of our extract


Our full spectrum phytocannabinoids therapies are synthesised exclusively in European Medicines Agency cGMP compliant production facilities.


Dosing pipettes make it easy and precise to use.

Copyright ©2023 Growlab Pharmaceuticals. All Rights Reserved.